These neoantigens can be recognized by the major histocompatibility complex (MHC) on antigen-presenting cells (APCs), and the resulting tumor-specific peptide-HLA complexes can be identified by T cells, thereby triggering an anti-tumor immune response (18). The gene discussed is HLA-C; the disease is neoplasm.